You just read:

PTC Therapeutics Announces New Analyses that Support the Potential Benefit of Ataluren in Preserving Lung Function in Non-Ambulatory Nonsense Mutation Duchenne Muscular Dystrophy Patients

News provided by

PTC Therapeutics, Inc.

06 Oct, 2016, 07:30 ET